Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2024: Cash: € 349,630.55 Number of shares ...

Inventiva est une société biopharmaceutique spécialisée dans la recherche et développement de petites molécules administrées par voie orale pour le traitement de patients atteints de la ...

Kepler Cheuvreux’s execution division KCx has expanded its execution access to the Middle East and Northern Africa (MENA). KCx’s expansion opens trading opportunities in the following countries: Dubai ...

24/01 FW Kepler Cheuvreux relève le prix cible pour Investor à 357 SEK (346) et réaffirme son intention de l'acheter. 24/01 FW DNB relève l'objectif de prix pour Investor à 345 SEK (330 ...

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...

Né le 20 août 1946 à Paris, Laurent Fabius a été un homme d'État majeur de la vie politique française depuis les années 1970. Après avoir adhéré au Parti socialiste (PS), il est ...

Kepler Cheuvreux initiated coverage of Rotork (RTOXF) with a Buy rating and 390 GBp price target The firm cites the company’s debt-free balance sheet and strong fundamentals for the Buy rating.

On Wednesday, Kepler Cheuvreux initiated coverage on Nexity (EPA:NEXI) SA (NXI:FP), a prominent player in the French real estate market, assigning a Hold rating to the company's shares. The research ...

On Wednesday, Kepler Cheuvreux began covering Kaufman & Broad S.A. (KOF:FP) (OTC: KFMNF) with a Buy rating and set a price target of €39.10. The firm's analysts pointed to the structural trends ...